Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma
Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma
复制标题
DOI：
10.1007/s12032-012-0446-y
复制
发表时间：
2013-03-01
期刊：
影响因子：
3.4
通讯作者：
Ascione, Antonio
中科院分区：
文献类型：
--
作者：
Di Costanzo, Giovan Giuseppe;Tortora, Raffaella;Ascione, Antonio
肝细胞癌（HCC）的发病率在全球范围内不断增加，预计未来几年老年肝细胞癌患者的比例将稳步上升。索拉非尼是晚期 HCC 患者的标准治疗方法，但缺乏关于老年肝硬化患者如何耐受这种药物的详细数据。因此，我们的目的是评估年龄对肝细胞癌和肝硬化患者索拉非尼靶向治疗效果的影响。我们分析了连续队列的不适合手术或局部治疗的 HCC 患者，并采用 Child-Pugh 评分
The incidence of hepatocellular carcinoma (HCC) is increasing worldwide and the proportion of older patients with HCC is expected to steadily rise in the next years. Sorafenib is the standard of care for patients with advanced HCC but there is a lack of detailed data on how older patients with cirrhosis tolerate this drug. Therefore, we aimed to evaluate the impact of age on the effects of sorafenib-targeted therapy in patients with HCC and cirrhosis. We analyzed a consecutive cohort of HCC patients not eligible for surgery or locoregional treatment, with Child-Pugh score